Autoantibody Status is not found to be Associated with Early Treatment Response to First-line MTX in Patients with Early RA

Primary tabs

SCIENCE
Autoantibody Status is not found to be Associated with Early Treatment Response to First-line MTX in Patients with Early RA
Key Take-Away: 

In this study, autoantibody status was not connected with early remission in newly diagnosed RA-patients receiving MTX in real-world clinical practice. Hence, the results from this study do not support the hypothesis that treatment should be modified to autoantibody status when it comes to starting MTX therapy as the first-line anti-rheumatic treatment. The results of this study specify that MTX is useful as an initial treatment strategy, notwithstanding the autoantibody status. 

Introduction:

The relationship between autoantibody status and treatment response to methotrexate (MTX) remains unclear in RA. The authors investigated the connection between autoantibody status and early remission in newly diagnosed RA patients treated with MTX using real-world data.

 

Methods:

RA-patients initially treated with MTX were selected from an international observational database (METEOR). Patients were stratified into autoantibody-positive (RF- and/or ACPA-positive) or autoantibody negative (RF- and ACPA-negative). The effect of autoantibody status on the chance of attaining remission within 3 to 6 months was analysed via Cox-proportional hazards regression.

 

Results:

Data from 1826 RA patients were available for analysis. DAS remission was achieved in 17% (318/1826). This was similar in autoantibody-positive [17% (282/1629)] and negative patients [18% (36/197)]. Hence, autoantibody positivity was not associated with remission [hazard ratio (HR) 0.89, 95% CI 0.57, 1.38]. Similar findings were found when stratified for MTX monotherapy (HR 0.75, 95% CI 0.41, 1.37) or combination treatment (HR 0.76, 95% CI 0.37, 1.54). Good physical function (HAQ < 0.5) was achieved in 33% (530/1590) of all patients. Autoantibody-positivity was also not associated with HAQ < 0.5 (HR 1.05, 95% CI 0.71, 1.57).

 

Conclusion:

Autoantibody status is not connected with early remission in newly diagnosed RA-patients receiving MTX. This indicates that MTX is useful as an initial treatment strategy regardless of autoantibody status.

Source

Rheumatology

Link:

https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/key263/5094544?redirectedFrom=fulltext

Original title of article:

Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis

Authors:

Jacqueline S Dekkers et al.

Exploratory, Methotrexate (MTX), Rheumatoid arthritis (RA)
Log in or register to post comments